Plain-English translation of NCT06722612 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing two different chemotherapy and targeted therapy combinations for patients with early HER2-positive breast cancer who have had surgery and have no lymph node involvement. One approach uses paclitaxel or docetaxel with carboplatin and trastuzumab; the other uses paclitaxel or docetaxel with both trastuzumab and pertuzumab. The goal is to find the most effective treatment with the fewest side effects.
Current standard treatment for this type of breast cancer uses chemotherapy plus trastuzumab, but doctors want to know if adding another targeted drug called pertuzumab might allow them to reduce the amount of chemotherapy needed while still keeping patients safe and cancer-free.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive either chemotherapy with one targeted drug or chemotherapy with two targeted drugs, given in 6 cycles (usually over several months). After that, you will continue with targeted therapy alone for up to 1 year. You will have regular follow-up visits to monitor how well the treatment is working and to track any side effects.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China